keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis definition

keyword
https://www.readbyqxmd.com/read/29904911/metabolic-syndrome-and-risk-of-incident-psoriasis-prospective-data-from-the-hunt-study-norway
#1
I Snekvik, T I L Nilsen, P R Romundstad, M Saunes
BACKGROUND: Metabolic syndrome has been associated with psoriasis in cross-sectional studies, but data from prospective studies are sparse. OBJECTIVES: To prospectively examine whether metabolic syndrome and its components are associated with risk of incident psoriasis in a large population-based study using objective measurements of cardiovascular disease risk factors. METHODS: We used data from two consecutive surveys of the HUNT Study, Norway (HUNT2, 1995-1997, and HUNT3, 2006-08)...
June 14, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29874363/core-outcome-sets-for-psoriasis-clinical-trials-definition-consensus-and-acceptance
#2
Bruce E Strober, Kenneth B Gordon
No abstract text is available yet for this article.
June 6, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29852521/generalized-pustular-psoriasis-a-model-disease-for-specific-targeted-immunotherapy-systematic-review
#3
REVIEW
Alexander Boehner, Alexander A Navarini, Kilian Eyerich
Generalized pustular psoriasis (GPP) psoriasis is a rare, multisystemic skin disease characterized by recurrent episodes of pustulation. GPP can be life-threatening and is often difficult to treat. In the era of precision medicine in dermatology, GPP stands exemplary for both challenges and chances - while new treatments offer great hope, there is urgent need for better definition and stratification of this severe and heterogeneous disease. Our objective was to systematically review the literature for evidence of efficacy of targeted immunotherapy and their mode of action in the context of clinical phenotype, classification and pathogenesis of adult GPP...
May 31, 2018: Experimental Dermatology
https://www.readbyqxmd.com/read/29848153/efficacy-and-survival-of-biologic-agents-in-psoriasis-a-practical-real-life-12-year-experience-in-a-french-dermatology-department
#4
Hélène Roche, Kevin Bouiller, Eve Puzenat, Elise Deveza, Blandine Roche, Fabien Pelletier, Alison van de Laak, Anne Sophie Dupond, Charlée Nardin, François Aubin
BACKGROUND: Drug survival in a real-life setting is critical to long-term use of biologics for psoriasis. OBJECTIVE: We describe our 12-year experience with biologics in psoriasis patients. PATIENTS AND METHODS: All patients treated with biologics including infliximab, adalimumab, etanercept and ustekinumab for psoriasis vulgaris between January 2005 and December 2016 were retrospectively analyzed. RESULTS: In total, 545 treatment series were administered to 269 patients, including 211 treatment series with adalimumab, 135 with etanercept, 77 with infliximab and 122 with ustekinumab...
May 31, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29792371/biologics-monitoring-incongruity-between-recommendations-and-clinician-monitoring-trends
#5
Anish Nadkarni, Kimberly Hyde, Leah A Cardwell, Steven R Feldman
BACKGROUND: Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients. OBJECTIVE: We aim to query a Humana database to gain insight regarding current dermatologist laboratory monitoring practices for psoriasis patients on biologics. METHODS: Data were obtained from the Humana database. Our cohort included 333 patients with primary ICD-9 diagnosis of psoriasis (696...
May 24, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29771924/obesity-and-response-to-anti-tumor-necrosis-factor-%C3%AE-agents-in-patients-with-select-immune-mediated-inflammatory-diseases-a-systematic-review-and-meta-analysis
#6
Siddharth Singh, Antonio Facciorusso, Abha G Singh, Niels Vande Casteele, Amir Zarrinpar, Larry J Prokop, Eduardo L Grunvald, Jeffrey R Curtis, William J Sandborn
OBJECTIVES: We sought to evaluate the association between obesity and response to anti-tumor necrosis factor-α (TNF) agents, through a systematic review and meta-analysis. METHODS: Through a systematic search through January 24, 2017, we identified randomized controlled trials (RCTs) or observational studies in adults with select immune-mediated inflammatory diseases-inflammatory bowel diseases (IBD), rheumatoid arthritis (RA), spondyloarthropathies (SpA), psoriasis and psoriatic arthritis (PsA)-treated with anti-TNF agents, and reporting outcomes, stratified by body mass index (BMI) categories or weight...
2018: PloS One
https://www.readbyqxmd.com/read/29730888/patient-perceptions-of-clear-almost-clear-skin-in-moderate-to-severe-plaque-psoriasis-results-of-the-clear-about-psoriasis-worldwide-survey
#7
A Armstrong, S Jarvis, W-H Boehncke, M Rajagopalan, P Fernández-Peñas, R Romiti, A Bewley, B Vaid, L Huneault, T Fox, M Sodha, R B Warren
BACKGROUND: Therapeutic advances have made the achievement of clear/almost clear skin possible for many patients with moderate-to-severe plaque psoriasis. OBJECTIVE: To determine patient perceptions of the impact of psoriasis and of attaining clear/almost clear skin. METHODS: Global survey of patients with moderate-to-severe psoriasis. RESULTS: 8338 patients from 31 countries participated. The majority (57%) had not achieved self-assessed clear/almost clear skin with their current therapy, and 56% of those who had not met this goal believed it would be impossible to do so...
May 6, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29729165/modern-specific-features-and-therapy-of-psoriasis-and-arthropathic-psoriasis-courses
#8
Orysya O Syzon, Marianna O Dashko, Ulyana V Fedorova
OBJECTIVE: Introduction:Psoriasis affects about 2% of population. In 30-40% of occurrences arthropathic psoriasis (AP) is diagnosed and it leads to 11-19% of disability cases development. Recent studies have shown that psoriasis is often synergistically combined with herpesvirus of the 1st and 2nd type, which, according to many scientists, determines the severity, frequency of recurrences, and the course of this dermatosis. Recently, new biomarkers, i.e. a system of small ribonucleic microRNA acids, have been described...
2018: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29718756/healthcare-resource-utilization-and-costs-among-psoriasis-patients-treated-with-biologics-overall-and-by-disease-severity
#9
Mwangi J Murage, Amanda Anderson, Susan A Oliveria, Deborah Casso, Clement K Ojeh, Talia M Muram, Joseph F Merola, Andre B Araujo
AIMS: To describe healthcare resource utilization (HCRU) and costs among biologic-treated psoriasis patients in the US, overall and by disease severity. MATERIALS AND METHODS: IQVIA PharMetrics Plus administrative claims data were linked with Modernizing Medicine Data Services Electronic Health Record data and used to select adult psoriasis patients between April 1, 2010 and December 31, 2014. Eligible patients were classified by disease severity (mild, moderate, severe) using a hierarchy of available clinical measures...
May 22, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29675414/spondyloarthritis-acute-anterior-uveitis-and-fungi-updating-the-catterall-king-hypothesis
#10
Martin Laurence, Mark Asquith, James T Rosenbaum
Spondyloarthritis is a common type of arthritis which affects mostly adults. It consists of idiopathic chronic inflammation of the spine, joints, eyes, skin, gut, and prostate. Inflammation is often asymptomatic, especially in the gut and prostate. The HLA-B*27 allele group, which presents intracellular peptides to CD8+ T cells, is by far the strongest risk factor for spondyloarthritis. The precise mechanisms and antigens remain unknown. In 1959, Catterall and King advanced a novel hypothesis explaining the etiology of spondyloarthritis: an as-yet-unrecognized sexually acquired microbe would be causing all spondyloarthritis types, including acute anterior uveitis...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29652832/sympathetic-nerve-hyperactivity-in-the-spleen-causal-for-nonpathogenic-driven-chronic-immune-mediated-inflammatory-diseases-imids
#11
REVIEW
Denise L Bellinger, Dianne Lorton
Immune-Mediated Inflammatory Diseases (IMIDs) is a descriptive term coined for an eclectic group of diseases or conditions that share common inflammatory pathways, and for which there is no definitive etiology. IMIDs affect the elderly most severely, with many older individuals having two or more IMIDs. These diseases include, but are not limited to, type-1 diabetes, obesity, hypertension, chronic pulmonary disease, coronary heart disease, inflammatory bowel disease, and autoimmunity, such as rheumatoid arthritis (RA), Sjőgren's syndrome, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and multiple sclerosis...
April 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29566966/considerations-for-the-definition-of-remission-criteria-in-psoriatic-arthritis
#12
REVIEW
Philip J Mease, Laura C Coates
OBJECTIVES: Psoriatic arthritis (PsA) is an autoimmune disease that can cause progressive structural damage of the joints and irreversible disability. The potentially achievable results of biologic therapy for PsA has led to the view that disease remission should be the goal of treatment. However, the heterogeneity of disease manifestations and need for validated outcome measures makes defining remission in PsA challenging. This article evaluates proposed criteria for defining remission in PsA and discusses how these criteria can be applied in clinical practice...
June 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29502473/defining-and-treating-moderate-plaque-psoriasis-a-dermatologist-survey
#13
Melissa L F Knuckles, Eugenia Levi, Jennifer Soung
PURPOSE: Patients with moderate plaque psoriasis are often undertreated and may experience unsatisfactory clinical outcomes. Undertreatment may stem partly from a lack of consensus on the definition of moderate psoriasis and appropriate treatments for patients with moderate disease severity. MATERIALS AND METHODS: An online survey was conducted during October 2015 to determine how US dermatologists in the clinical setting define and treat moderate psoriasis. RESULTS: A total of 150 dermatologists responded to the survey (mean time in practice: 13...
March 22, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29493005/use-of-topical-therapies-for-pediatric-psoriasis-a-systematic-review
#14
REVIEW
Georgios Kravvas, Karolina Gholam
Psoriasis is one of the most common chronic skin diseases, affecting 1%-3% of the general population. It can have a significant negative impact on a patient's quality of life, and in approximately 30% of patients first symptoms can be traced back to childhood. We have performed a comprehensive literature search using the MEDLINE database in order to ascertain the efficacy and adverse reactions of topical treatments in pediatric psoriasis. A total of 13 relevant articles were identified on the following topical agents: corticosteroids, calcineurin inhibitors, vitamin D analogs, and dithranol...
May 2018: Pediatric Dermatology
https://www.readbyqxmd.com/read/29482382/guselkumab-for-the-treatment-of-psoriasis
#15
Matteo Megna, Anna Balato, Annunziata Raimondo, Nicola Balato
Psoriasis is a chronic immune mediated disease in which the interplay of T cells and keratinocytes seems to play a key role. In this context, the interleukin (IL)-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis and the selective inhibition of IL-23 may be viewed as an improvement of treatments blocking both IL-23 and IL-12, since its upstream actions. Areas covered: The authors performed a thorough and updated review on guselkumab, a fully human IgG1λ monoclonal antibody that blocks the p19 subunit of IL-23, analyzing efficacy and safety data from phase I, II and III trials...
April 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29480455/ixekizumab-for-treating-moderate-to-severe-plaque-psoriasis-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#16
REVIEW
Bram L T Ramaekers, Robert F Wolff, Xavier Pouwels, Marije Oosterhoff, Anoukh Van Giessen, Gill Worthy, Caro Noake, Nigel Armstrong, Jos Kleijnen, Manuela A Joore
The National Institute for Health and Care Excellence invited Eli Lilly and Company Ltd, the company manufacturing ixekizumab (tradename Taltz® ), to submit evidence for the clinical and cost effectiveness of ixekizumab. Ixekizumab was compared with tumour necrosis factor-α inhibitors (etanercept, infliximab, adalimumab), ustekinumab, secukinumab, best supportive care and, if non-biological treatment or phototherapy is suitable, also compared with systemic non-biological therapies and phototherapy with ultraviolet B radiation for adults with moderate-to-severe plaque psoriasis...
February 26, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29464730/demyelination-during-anti-tumour-necrosis-factor-therapy-for-psoriasis
#17
J M E Boggs, L Barnes
Anti-tumour necrosis factor (anti-TNF) therapies have been associated with neurological complications, including in rare cases demyelinating disease. It is currently unknown whether patients who have received more than one immunosuppressive agent or anti-TNF have a greater risk of demyelination. We report the case of a 37-year-old woman with psoriasis who presented with an acute episode of demyelination while on anti-TNF therapy. This case was complicated by the fact that progressive multifocal leukoencephalopathy was considered the likely diagnosis initially and was only definitively excluded by brain biopsy...
February 21, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29398124/prevalence-and-incidence-of-psoriatic-arthritis-a-systematic-review-and-meta-analysis
#18
Lorenza Scotti, Matteo Franchi, Antonio Marchesoni, Giovanni Corrao
BACKGROUND: Psoriatic arthritis (PsA) is a specific form of inflammatory arthritis associated with psoriasis affecting in the same measure men and women but with a consistent geographic variability. Since the burden of PsA frequency has important implications in the definition of the healthcare policies, it is important to measure the frequency of disease in the general population. OBJECTIVE: To quantify the global health burden of PsA summarizing the data provided by the population-based available studies investigating prevalence and incidence of the disease...
January 6, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29318966/chronic-inflammatory-diseases-and-atherosclerotic-cardiovascular-disease-innocent-bystanders-or-partners-in-crime
#19
Peter Riis Hansen
Inflammation plays a significant role in atherosclerosis and cardiovascular disease (CVD). Patients with chronic inflammatory diseases are at increased risk of CVD, but it is debated whether this association is causal or dependent on shared risk factors, other exposures, genes, and/or inflammatory pathways. The current review summarizes epidemiological, clinical, and experimental data supporting the role of shared inflammatory mechanisms between atherosclerotic CVD and rheumatoid arthritis, psoriasis, inflammatory bowel disease, and periodontitis, respectively, and provides insights to future prospects in this area of research...
2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29303139/temporomandibular-joint-involvement-in-psoriatic-arthritis
#20
Alime Okkesim, Mehmet Zahit Adisen, Melda Misirlioglu
Psoriasis is a chronic, papulosquamous, and an inflammatory skin disease. It has been found that between 5% and 24% of patients develop psoriatic arthritis (PA) at the same time after or even prior to skin findings. The involvement of temporomandibular joint (TMJ) is a rare condition. In this report, a-46-year-old male patient was referred to our clinic with the complaint of pain in the bilateral TMJs, and a limited jaw movement. Medical anamnesis revealed he had psoriasis for the last 21 years, and developed a seronegative polyarthritis with destructive changes for 8 years...
November 2017: Nigerian Journal of Clinical Practice
keyword
keyword
110315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"